Aptose Biosciences Inc.
251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828
https://www.aptose.com
版塊: Healthcare
行業: Biotechnology
全職員工: 35
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Fletcher Payne | Senior VP, CFO, Chief Business Officer & Secretary | 470.9k | 無 | 1963 |
| Dr. Marc Wiles Ph.D. | Senior Vice President of Regulatory Affairs | 無 | 無 | 無 |
| Mr. Brooks Ensign M.B.A. | VP & Controller | 無 | 無 | 無 |
描述
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
公司管治
截至 2024年4月29日 止，Aptose Biosciences Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：8；股東權利：7；現金賠償：9。
